CAPN3 and cancer: Subsequently, NCL-1 derivatives were developed with the aim of improving their biological activity [112], and these analogues exhibited good anti-cancer activities in solid tumors, such as breast cancer [119], prostate cancer [120], and glioma [121,122] in cellulo and/or in vivo.